Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C001 - Comprehensive Approach to Neuromodulators and Fillers in 2019

Friday, July 26; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe the age-related changes in the face and body and how they relate to treatment choices
  • Assess sites. of treatment, predict potential complications and manage them
  • Compare available fillers and neuromodulators to design customized treatment regimens

Description

Treating patients with fillers/neurotoxins has two goals- to slow down the aging process, reverse signs of aging and improve whole body aesthetics in a personalized/customizable manner. It is a 360 approach, which takes into account a patient’s specific desires and their individual anatomy to volumetrically structurally rejuvenate the face and body. This session is directed to experienced and novice dermatologists, physician assistants, fellows and nurses that are interested in the latest cutting edge strategies for rejuvenating the face and body, based on new knowledge on anatomy, and using the latest neuromodulators/fillers.

Disclosures

  • Alam, Murad, MD: Pulse Biosciences – C(Fees);
  • Arruda, Suleima, MD: no financial relationships exist with commercial interests.
  • Butterwick, Kimberly J., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(H); Colorescience – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Histogen Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – A(H); Revance Therapeutics, Inc. – A(H); Sinclair Pharma, LLC – Speaker/Faculty Education(H);
  • Cotofana, Sebastian, MD, PhD: no financial relationships exist with commercial interests.
  • Farah, Ronda S., MD: Capillus Laser Caps – O(EQ); Early Sullivan Wright Gizer & McRae LLP – C(NC); Eclipse Medical – O(Grants/Research Funding); Gilead Sciences – SH(NC); HairMax – O(EQ); Inovio Pharmaceuticals, Inc – SH(NC); LaserCap – O(EQ); Pfizer Inc. – SH(NC); Syneron Candela – O(Grants/Research Funding); Theradome – O(EQ); WEN – I(Grants/Research Funding);
  • Gonzalez, Noelani, MD: no financial relationships exist with commercial interests.
  • Hordinsky, Maria K., MD: Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Concert Pharmaceuticals – C(Fees); Incyte Corporation – O(Grants/Research Funding); Procter & Gamble Company – C(H); UpToDate, Inc – I(Grants/Research Funding);
  • Mikkilineni, Radha, MD: no financial relationships exist with commercial interests.
  • Sadick, Neil S., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Allergan, Inc. – C(H), O(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H); Derm Advance – SH(SO); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Incyte Corporation – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Pfizer Inc. – I(Grants/Research Funding); Philips Healthcare – I(Grants/Research Funding); Prescriber's Choice – O(H); Regeneron – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Sol-Gel Technologies – I(Grants/Research Funding); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Wu, Douglas, MD, PhD: Allergan, Inc. – Speaker/Faculty Education(H); Galderma USA – Speaker/Faculty Education(H); Syneron Candela – C(H);
Schedule
Friday, July 26
1:00 PM
Dr. Hordinsky / Anatomic Considerations for neuromodulators
1:15 PM
Dr. Gonzalez / Upper and lower face treatment with neuromodulators
1:30 PM
Dr. Wu / New uses for neuromodulators
1:45 PM
Dr. Cotofana / Anatomic consideration for fillers: avoiding danger zones
2:00 PM
Dr. Sadick / Volumetric structural rejuvenation
2:15 PM
Dr. Arruda / Periocular and perioral rejuvenation
2:30 PM
Dr. Butterwick / Off face use of fillers
2:45 PM
/ Break
3:00 PM
Dr. Mikkilineni / The male perspective for fillers/neuromodulators
3:15 PM
Dr. Sadick / Combining fillers/neuromodulators with energy-based devices
3:30 PM
Dr. Farah / Preventing and managing complications
3:45 PM
/ Panel discussion/Q&A
Event Details
  • Date
    Friday, July 26
  • Time
    1:00 PM - 4:00 PM
  • Location
    Mercury Ballroom
  • CME Credits
    3.00
  • Type
    Ticketed
    Restricted
Directors/Co-Directors
  • Neil S. Sadick, MD, FAAD
Speakers
  • Douglas Wu, MD, PhD
  • Kimberly J. Butterwick, MD, FAAD
  • Maria K. Hordinsky, MD, FAAD
  • Murad Alam, MD, FAAD
  • Noelani Gonzalez, MD, FAAD
  • Radha Mikkilineni, MD, FAAD
  • Ronda S. Farah, MD, FAAD
  • Sebastian Cotofana, MD, PhD
  • Suleima Arruda, MD